First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19

Urine 11-dehydro-thromboxane B-2 (u11-dh-TxB(2)), 8-hydroxy-2'-deoxyguanosine (8-OHdG), and liver-type fatty acid binding protein levels (L-FABP) at the time of hospitalization were higher in coronavirus disease 2019 (COVID-19) patients with adverse events vs without events. Higher u11-dh-TxB(2) and L-FABP levels were associated with longer hospitalization, more thrombotic events, and greater mortality, providing evidence for potential utility as early prognostic biomarkers for COVID-19.

Automated summary

Higher levels of urine 11-dehydro-thromboxane B-2 and liver-type fatty acid binding protein at hospitalization were associated with longer hospital stay, more thrombotic events, and higher mortality in COVID-19 patients, suggesting their potential utility as early prognostic biomarkers.